SOLASIA LAUNCHES SANCUSO® IN CHINA
- Sancuso®, the First Transdermal Patch for the Prevention of CINV Launched in China
Opening up a New Chapter for Whole Process CINV Management -

Tokyo, Japan, March 18, 2019—Solasia Pharma K.K. (TOKYO:4597, Headquarters:Tokyo, Japan, President & CEO:Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today officially announced that the Company has launched the granisetron transdermal patch “Sancuso®” (SP-01, product name in China: 善可舒®, hereinafter “Sancuso®”) in China.

Solasia and Lee’s Pharmaceutical (HK) Ltd. (hereinafter “Lee’s”) jointly held the China national launch meeting of Sancuso® (Granisetron Transdermal System) in Shanghai on March 16. Sancuso® is the world’s first and only transdermal patch of the 5-HT3 receptor antagonist used for the prevention of nausea and vomiting in patients receiving moderately or highly emetic chemotherapy regimens. After being approved by FDA in 2008, Sancuso® was launched in over 20 countries and regions and recommended by international and Chinese guidelines.

Sancuso® China national launching meeting as “Hand in hand with Sancuso® - whole process CINV management program” was successfully held in Shanghai. Professor Li Jin, chairman of CSCO (Chinese Society of Clinical Oncology), Professor Qin Shukui and Professor Ma Jun, the vice chairman of CSCO were chairmen of the meeting. Nearly 200 oncology experts from all over the country gathered together to discuss and share the current status and development of cancer supportive care, chemotherapy induced nausea and vomiting (CINV) management, clinical experience of CINV management, and key clinical data of Sancuso®.

The head of CSCO and the Foundation, well-known national oncology expert, and the primary investigator of the Chinese registration trial (Pi), Professor Qin Shukui expressed his warm congratulation on Sancuso’s successful launch in China. He said: "Without any anti-emetic measures, 70%-80% of chemotherapy patients would experience CINV which would severely affect their quality of life. Often, patients will have to be treated with reduced dosage or even withdrawn from chemotherapy, with negative impacts on the treatment outcomes. The traditional CINV prevention methods are mainly short-term intravenous injection, which due to great fluctuation in blood concentration, requires repeated administration which is inconvenient for patients. With unique transdermal system, Sancuso® gradually releases granisetron into blood every day for up to 7 days. With one patch per one chemotherapy cycle, it is a new non-invasive treatment choice for chemotherapy patients."

"CINV whole process management is the consensus and principle of CINV treatment consistently advocated in national and international guidelines." Professor Ma Jun further pointed out that "The emetic risk in patients receiving HEC and MEC chemotherapy will continue for 2-3 days after last dose of chemotherapy. For multi-day chemotherapy, there is an overlap between acute and delayed vomiting, which requires more stable and long-lasting drug. Sancuso® covers different emetic stages including expected, acute and delayed nausea and vomiting. The 7 day stable efficacy makes the whole process CINV management possible and allows patients to feel at ease throughout the entire chemotherapy cycle."

Professor Li Jin points out: “The successful launching of Sancuso provides a long-lasting, stable and non-invasive new choice for the prevention of nausea and vomiting in Chinese chemotherapy patients. As a new choice for the prevention and treatment of chemotherapy related vomiting, with one patch, which is simple and easy, it makes CINV whole process management more convenient, it helps to standardize clinical treatment of CINV and further improves the treatment rate of CINV."

With the support by CSCO-SCRC, and jointly organized by Solasia and Lee’s, “Hand in hand with Sancuso®—whole process CINV management program”, was also launched during the conference. "Hand in hand with Sancuso®" aims to promote the standardization of CINV treatment, improve the control rate of CINV, and as a result, enhance patients’ quality of life. Through in-hospital education, out-of-hospital care hotline, and online whole process management diary, the program helps patients understand the disease, experience whole process care, and receive in time help and support. The program also establishes CINV whole process management database for doctors to track patient’s occurrence and development of CINV in real time, enabling doctors to promptly react to severe vomiting episodes in time, and helps doctors to formulate and optimize subsequent courses of treatment. The CINV real world data which is compiled through patients reported outcome (PRO), provides the basis and
guidance for the standardized management of CINV. The project is supported and affirmed by experts in the field, and more than 20 centers will participate in the program to jointly establish standardized CINV whole process management.

Yoshihiro Arai, President and Chief Executive Officer, Solasia, said: “Solasia company mission is ‘Better Medicine for a Brighter Tomorrow’. We have always focused on the patients, and striven to develop innovative products in the field of cancer treatment and supportive care. With our policy to bring ‘quality medicines’ to the market, we aim to benefit more patients in China, Japan and other Asian countries. The launch of Sancuso® and the co-promotion by Solasia and Lee’s is our first step of unwavering commitment to Chinese patients. All of Solasia and Lee’s team members will continue to work hard to meet the needs of patients and healthcare professionals and embrace new challenges going forward.”

**About Sancuso®**

Sancuso® is the Granisetron transdermal system used for the prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy regimens. Each 52cm² patch contains 34.3mg of Granisetron and releases 3.1mg of Granisetron every 24 hours for up to 7 days. Granisetron transdermal system is a persistently effective noninvasive drug delivery system with a proven safety profile. To date, Sancuso® has been launched in over 20 countries and regions including the United States, UK, Germany, the Netherlands, and Denmark. In 2014, a clinic pharmacology study as well as a random and double-blind clinical study versus oral Granisetron was completed in China. In July 2018, it was finally approved by the China National Medical Products Administration (NMPA).

**About Solasia**

Solasia is an Asia-based pharmaceutical company dedicated to developing and selling innovative cancer treatment supportive drugs for local markets. As to benefit patients in China, the company is focused on creating a cancer treatment system in Asia, by developing innovative cancer drugs, introducing and getting commercial development licenses for great products from leading pharmaceutical and biotech companies in Japan, Europe and U.S.A, and other Asian countries. Solasia actively responds to the needs of patients and healthcare professionals and works hard to improve patient’s life and meet the key unmet needs in oncology. For more information about the company, please visit [www.solasia.co.jp/en/](http://www.solasia.co.jp/en/)

(Contact)

**Solasia Pharma K.K.**

Rie Toyoda, Public Relations and Investor Relations
Tel: +81 3 5843 8049 (Japan)
info@solasia.co.jp

**Solasia Medical Information Consulting (Shanghai) Co. Ltd.**

Aili Xu, Director, Marketing Department
Tel: +86 21 5068 6185 (China)
info1@solasia.com.cn

---

3. NCCN. Clinical Practice Guidelines in Oncology. Antiemesis. 2019; Version 1
5. MASCC/ESMO Antiemetic Guideline